

Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023

<https://marketpublishers.com/r/G0F8A8AE65D5EN.html>

Date: November 2022

Pages: 130

Price: US\$ 1,800.00 (Single User License)

ID: G0F8A8AE65D5EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023 Report Highlights:

Global Anti TIGIT Antibodies Market Dynamics

Insight On Anti TIGIT Antibodies Clinical Trials Insight By Phase, Company, Country, Indication

Anti TIGIT Antibodies In Clinical Trials: > 45

Overview On Partnerships & Collaborations In The Global Anti TIGIT Antibodies Market

Global Anti TIGIT Antibodies Market Outlook

Competitive Landscape

The advancement in the field of genomics has led to identification of T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) as a promising emerging immune checkpoint target. TIGIT indirectly suppresses T-cell activation and is expressed on multiple types of immune cells, including regulatory T (Treg) cells, activated T cells, and natural killer (NK) cells. TIGIT is up regulated in T cells and NK cells after ligand binding, inhibiting these cells' ability to kill tumor cells. Increased TIGIT expression is also associated with advanced disease and poor survival

outcomes. Additionally, increased TIGIT expression after treatment is associated with disease recurrence.

Since its identification as potential immunotherapy target, pharmaceutical companies have developed a robust pipeline of TIGIT inhibitors and are reporting promising preclinical and clinical trial results. Recently, iTeos Therapeutics has announced promising preclinical and clinical analyses supporting the multifaceted mechanism of action of its anti-TIGIT antibody, EOS-448/GSK4428859A, which is being developed in collaboration with GlaxoSmithKline. Various combinations of anti-TIGIT antibody isotopes have been studied in cancer models of mouse. Depending on the isotope used, the preclinical analyses of these combinations have demonstrated different anti-tumor activities. Strong anti-tumor activities have been found while using the isotope engaging the Fc γ R, which has been linked to the activation of effector CD8 T cells and the reduction in the number of Treg cells in the tumor microenvironment. EOS-448 has further shown to induce the depletion of the precursors of exhausted T cells in addition to regulatory T cells, but not of stem-like memory T cells.

The recent years have seen an increase in collaborations and partnerships between companies for a faster development of novel drugs. Shanghai Junshi Biosciences and Coherus Bioscience recently announced that the two are taking their immuno-oncology collaboration agreement further by allowing Coherus to initiate its option to license the former's potential anti-TIGIT antibody - JS 006 - in the US and China. Regulatory bodies of the two regions have already approved the drug's Investigational new drug (IND) applications, allowing the companies to develop it further clinically. Apart from this, clinical trials are ongoing which are assessing the drug's safety, pharmacokinetic properties and tolerability post dose escalation and expansion, as a monotherapy and in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors.

Apart from these trends in the market, the pipeline of novel TIGIT inhibitor is highly crowded which suggests promising future of the market. The key drugs in research and development include including AB 154, Ociperlimab, COM902, EOS448, Tiragolumab, and others. As per our analysis, TIGIT inhibitor is expected to enter the market by 2024, which will transform the overall immunotherapy market during the forecast period. However, the market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years.

As per our report findings, the global market is expected to have opportunity of more than US\$ 300 Million once the first Anti TIGIT antibody is commercially approved in coming years. The Anti TIGIT Antibody clinical development and market opportunity is driven by the rising occurrence of different forms of cancer, technological advancements in the field of immune-oncology for cancer treatment, and rising awareness concerning the benefits of targeted therapies over conventional cancer therapies. Apart from this, rising government initiatives, increasing awareness among population, and development of favorable reimbursement policies is also boosting the growth of market during the forecast period.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product's mechanism of action, dosage and administration, and other development activities.

Contents

1. INTRODUCTION TO TIGIT INHIBITOR

2. ROLE OF TIGIT INHIBITORS BY INDICATIONS

- 2.1 TIGIT Inhibitors in Cancer
- 2.2 TIGIT Inhibitors in HIV
- 2.3 TIGIT in Autoimmune Disorders

3. MECHANISM OF ANTI TIGIT ANTIBODIES

- 3.1 Overview
- 3.2 Clinical Approaches to Target TIGIT

4. PARTNERSHIPS & COLLABORATIONS IN THE GLOBAL ANTI TIGIT ANTIBODIES MARKET

5. GLOBAL TIGIT INHIBITORS CLINICAL TRIALS OVERVIEW

- 5.1 By Company
- 5.2 By Country
- 5.3 By Indication
- 5.4 By Patient Segment

6. GLOBAL ANTI TIGIT ANTIBODY CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 6.1 Research
- 6.2 Preclinical
- 6.3 Phase-I
- 6.4 Phase-I/II
- 6.5 Phase-II
- 6.6 Phase-III

7. FDA ORPHAN DESIGNATION FOR TIRAGOLUMAB

8. GLOBAL ANTI TIGIT ANTIBODY MARKET DYNAMICS

8. 1 Market Drivers

8. 2 Commercialization Challenges

9. GLOBAL TIGIT INHIBITOR MARKET FUTURE OUTLOOK

10. COMPETITIVE LANDSCAPE

10.1 Arcus Biosciences

10.2 Agenus

10.3 Astellas Pharma

10.4 AstraZeneca

10.5 BeiGene

10.6 Bristol Myers Squibb

10.7 Compugen

10.8 Gilead Sciences

10.9 iTeos Therapeutics

10.10 Merck

10.11 Roche

10.12 Seagen

10.13 Shanghai Henlius Biotech

List Of Figures

LIST OF FIGURES

- Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
- Figure 2-1: Enhanced Anti-Tumor Effects of Dual TIGIT & PD-1 Blockade
- Figure 2-2: Blockade of TIGIT on Tregs Reduces Their Immunosuppressive Functions
- Figure 2-3: Blockade of TIGIT on NK Cells Augments Anti-Tumor Immunity
- Figure 2-4: Hypothetical Outcomes of Using TIGIT Blockade for HIV-1 Therapy
- Figure 2-5: TIGIT Associated Autoimmune Disorders
- Figure 3-1: TIGIT Inhibitor – Proposed Mechanism of Action
- Figure 3-2: TIGIT Inhibitor – Mechanism of Action
- Figure 3-3: Binding Efficacy of Monoclonal Antibody
- Figure 3-4: Binding Efficacy of Bispecific Antibodies
- Figure 3-5: Advantages of Small Molecule Drugs over Therapeutic Antibodies
- Figure 5-1: Global – Anti TIGIT Antibodies Clinical Trials by Company, 2023
- Figure 5-2: Global – Anti TIGIT Antibodies Clinical Trials by Country, 2023
- Figure 5-3: Global – Anti TIGIT Antibodies Clinical Trials By Indication, 2023
- Figure 5-4: Global – Anti TIGIT Antibodies Clinical Trials by Patient Segment, 2023
- Figure 7-1: Tiragolumab - SKYSCRAPER08 Phase-III Trial Initiation & Completion Year
- Figure 8-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 8-2: Global – TIGIT Inhibitor Market Drivers
- Figure 8-3: Stages of Drug Development

I would like to order

Product name: Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023

Product link: <https://marketpublishers.com/r/G0F8A8AE65D5EN.html>

Price: US\$ 1,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0F8A8AE65D5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970